JunD mediates androgen-induced oxidative stress in androgen dependent LNCaP human prostate cancer cells

Prostate

Volumn 68, Issue 9, 2008, Pages 924-934

  Mehraein Ghomi, Farideh ^a   Lee, Elyse ^a,b   Church, Dawn R ^a   Thompson, Todd A ^a,c   Basu, Hirak S ^a   Wilding, George ^a  

^a UNIVERSITY OF WISCONSIN   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF NEW MEXICO   (United States)

Author keywords

AP 1 transcription factor; JunD overexpression; JunD silencing; Reactive oxygen species

Indexed keywords

ANDROGEN; REACTIVE OXYGEN METABOLITE; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR JUND;

ARTICLE; CANCER GROWTH; CANCER RECURRENCE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL STRAIN LNCAP; CONTROLLED STUDY; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; OXIDATIVE STRESS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

BLOTTING, WESTERN; CELL LINE, TUMOR; GENETIC VECTORS; HORMONE ANTAGONISTS; HUMANS; MALE; METRIBOLONE; NEOPLASMS, HORMONE-DEPENDENT; OXIDATIVE STRESS; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-JUN; REACTIVE OXYGEN SPECIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, NEOPLASM; RNA, SMALL INTERFERING; TRANSCRIPTION FACTOR AP-1; TRANSDUCTION, GENETIC; TRANSFECTION;

EID: 44849134637     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20737     Document Type: Article

References (51)

1. Bostwick DG, Burke HB, Djakiew D, Euling S, Ho SM, Landolph J, Morrison H, Sonawane B, Shifflett T, Waters DJ, Timms B. Human prostate cancer risk factors. Cancer 2004;101 (10 Suppl.):2371-2490.
2. Wilding G. Endocrine control of prostate cancer. Cancer Surv 1995;23:43-62.
3. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghaffor A, Feuer EJ, Thun MJ. Cancer statistics, 2005. CA Cancer J Clin 2005;55(1):10-30.
4. Bokov A, Chaudhuri A, Richardson A. The role of oxidative damage and stress in aging. Mech Ageing Dev 2004;125(10-11):811-826.
5. Sies H. Oxidative stress: From basic research to clinical application. Am J Med 1991;91(3C):31S-38S.
6. Newmeyer DD, Ferguson-Miller S. Mitochondria: Releasing power for life and unleashing the machineries of death. Cell 2003;112:481-490.
7. Klaunig JE, Kamendulis LM. The role of oxidative stress in carcinogenesis. Annu Rev Pharmacol Toxicol 2004;44:239-267.
8. Nelson WG, De Marzo AM, DeWeese TL, Isaacs WB. The role of inflammation in the pathogenesis of prostate cancer. J Urol 2004;172(5 Pt 2):S6-S12; discussion S11-S12.
9. Lau KM, Tam NN, Thompson C, Cheng RY, Leung YK, Ho SM. Age- associated changes in histology and gene-expression profile in the rat ventral prostate. Lab Invest 2003;83(5):743-757.
10. Reyes I, Reyes N, Iatropoulos M, Mittelman A, Geliebter J. Aging-associated changes in gene expression in the ACI rat prostate: Implications for carcinogenesis. Prostate 2005;63(2):169-186.
11. Ripple MO, Henry WF, Rago RP, Wilding G. Prooxidant-antioxidant shift induced by androgen treatment of human prostate carcinoma cells. J Natl Cancer Inst 1997;89(1):40-48.
12. Ripple MO, Henry WF, Schwarze SR, Wilding G, Weindruch R. Effect of antioxidants on androgen-induced AP-1 and NF-κB DNA-binding activity in prostate carcinoma cells. J Natl Cancer Inst 1999;91(14):1227-1232.
13. Zerbini LF, Wang Y, Cho JY, Libermann TA. Constitutive activation of nuclear factor kappaB p50/p65 and Fra-1 and JunD is essential for deregulated interleukin 6 expression in prostate cancer. Cancer Res 2003;63(9):2206-2215.
14. Bostwick DG, Alexander EE, Singh R, Shan A, Qian J, Santella RM, Oberley LW, Yan T, Zhong W, Jiang X, Oberley TD. Anti-oxidant enzyme expression and reactive oxygen species damage in prostatic intraepithelial neoplasia and cancer. Cancer 2000;89(1):123-134.
15. Tam NN, Ghatak S, Ho SM. Sex hormone-induced alterations in the activities of antioxidant enzymes and lipid peroxidation status in the prostate of Noble rats. Prostate 2003;55(1):1-8.
16. Tam NN, Gao Y, Leung YK, Ho SM. Androgenic regulation of oxidative stress in the rat prostate: Involvement of NAD(P)H oxidases and antioxidant defense machinery during prostatic involution and regrowth. Am J Pathol 2003;163(6):2513-2522.
17. Zhong W, Yan T, Webber MM, Oberley TD. Alteration of cellular phenotype and responses to oxidative stress by manganese superoxide dismutase and a superoxide dismutase mimic in RWPE-2 human prostate adenocarcinoma cells. Antioxid Redox Signal 2004;6(3):513-522.
18. Fu M, Wang C, Wang J, Zhang X, Sakamaki T, Yeung YG, Chang C, Hopp T, Fuqua SA, Jaffray E, Hay RT, Palvimo JJ, Janne OA, Pestell RG. Androgen receptor acetylation governs trans-activation and MEKK1-induced apoptosis without affecting in vitro sumoylation and trans-repression function. Mol Cell Biol 2002;22(10):3373-3388.
19. Nakayama M, Bennett CJ, Hicks JL, Epstein JI, Platz EA, Nelson WG, De Marzo AM. Hypermethylation of the human glutathione S-transferase-pi gene (GSTP1) CpG island is present in a subset of proliferative inflammatory atrophy lesions but not in normal or hyperplastic epithelium of the prostate: A detailed study using laser-capture microdissection. Am J Pathol 2003;163(3):923-933.
20. Hatziapostolou M, Polytarchou C, Katsoris P, Courty J, Papadimitriou E. Heparin affin regulatory peptide/pleiotrophin mediates fibroblast growth factor 2 stimulatory effects on human prostate cancer cells. J Biol Chem 2006;281(43):32217-32226.
21. Shaulian E, Karin M. AP-1 as a regulator of cell life and death. Nat Cell Biol 2002;4(5):E131-E136.
22. Eferl R, Wagner EF. AP-1: A double-edged sword in tumorigenesis. Nat Rev Cancer 2003;3(11):859-868.
23. Church DR, Lee E, Thompson TA, Basu HS, Ripple MO, Ariazi EA, Wilding G. Induction of AP-1 activity by androgen activation of the androgen receptor in LNCaP human prostate carcinoma cells. Prostate 2005;63(2):155-168.
24. Hirai SI, Ryseck RP, Mechta F, Bravo R, Yaniv M. Characterization of junD: A new member of the jun proto-oncogene family. EMBO J 1989;8(5):1433-1439.
25. Agarwal SK, Guru SC, Heppner C, Erdos MR, Collins RM, Park SY, Saggar S, Chandrasekharappa SC, Collins FS, Spiegel AM, Marx SJ, Burns AL. Menin interacts with the AP1 transcription factor JunD and represses JunD-activated transcription. Cell 1999;96(1):143-152.
26. De Graeve F, Bahr A, Sabapathy KT, Hauss C, Wagner EF, Kedinger C, Chatton B. Role of the ATFa/JNK2 complex in Jun activation. Oncogene 1999;18(23):3491-3500.
27. Li Y, Jaiswal AK. Regulation of human NAD(P)H:quinone oxidoreductase gene. Role of AP1 binding site contained within human antioxidant response element. J Biol Chem 1992;267(21):15097-15104.
28. Liberati NT, Datto MB, Frederick JP, Shen X, Wong C, Rougier-Chapman EM, Wang XF. Smads bind directly to the Jun family of AP-I transcription factors. Proc Natl Acad Sci USA 1999;96(9):4844-4849.
29. Thebault S, Basbous J, Hivin P, Devaux C, Mesnard JM. HBZ interacts with JunD and stimulates its transcriptional activity. FEBS Lett 2004;562(1-3):165- 170.
30. Pfarr CM, Mechta F, Spyrou G, Lallemand D, Carillo S, Yaniv M. Mouse JunD negatively regulates fibroblast growth and antagonizes transformation by ras. Cell 1994;76(4):747-760.
31. Gerald D, Berra E, Frapart YM, Chan DA, Giaccia AJ, Mansuy D, Pouyssegur J, Yaniv M, Mechta-Grigoriou F. JunD reduces tumor angiogenesis by protecting cells from oxidative stress. Cell 2004;118(6):781-794.
32. Castellazzi M, Spyrou G, La Vista N, Dangy JP, Piu F, Yaniv M, Brun G. Overexpression of c-jun, junB, or junD affects cell growth differently. Proc Natl Acad Sci USA 1991;88(20):8890-8894.
33. Li L, Liu L, Rao JN, Esmaili A, Strauch ED, Bass BL, Wang JY. JunD stabilization results in inhibition of normal intestinal epithelial cell growth through P21 after polyamine depletion. Gastroenterology 2002;123(3):764-779.
34. Naito J, Kaji H, Sowa H, Hendy GN, Sugimoto T, Chihara K. Menin suppresses osteoblast differentiation by antagonizing the AP-1 factor, JunD. J Biol Chem 2005;280(6):4785-4791.
35. Wang H, Xie Z, Scott RE. Differentiation modulates the balance of positive and negative JunD/AP-1 DNA binding activities to regulate cellular proliferation potential: Different effects in nontransformed and transformed cells. J Cell Biol 1996;135(4):1151-1162.
36. Weitzman JB, Fiette L, Matsuo K, Yaniv M. JunD protects cells from p53-dependent senescence and apoptosis. Mol Cell 2000;6(5):1109-1119.
37. Hock TD, Liby K, Wright MM, McConnell S, Schorpp-Kistner M, Ryan TM, Agarwal A. JunB and JunD regulate human heme oxygenase-1 gene expression in renal epithelial cells. J Biol Chem 2007;282(9):6875-6886.
38. Horoszewicz JS, Leong SS, Kawinski E, Karr J, Rosenthal H, Chu T, Mirand E, Murphy G. LNCaP model of human prostate carcinoma. Cancer Res 1983;43:1809-1818.
39. Bonne C, Raynaud JP. Methyltrienolon, a specific ligand for cellular androgen receptors. Steroids 1975;26(2):227-232.
40. Ripple MO, Hagopian K, Oberley TD, Schatten H, Weindruch R. Androgen-induced oxidative stress in human LNCaP prostate cancer cells is associated with multiple mitochondrial modifications. Antioxid Redox Signal 1999;1(1):71-81.
41. Thepot D, Weitzman JB, Barra J, Segretain D, Stinnakre MG, Babinet C, Yaniv M. Targeted disruption of the murine junD gene results in multiple defects in male reproductive function. Development 2000;127(1):143-153.
42. Tsuji Y. JunD activates transcription of the human ferritin H gene through an antioxidant response element during oxidative stress. Oncogene 2005;24(51):7567-7578.
43. Krappmann D, Wegener E, Sunami Y, Esen M, Thiel A, Mordmuller B, Scheidereit C. The IkappaB kinase complex and NF-kappaB act as master regulators of lipopolysaccharide-induced gene expression and control subordinate activation of AP-1. Mol Cell Biol 2004;24(14):6488-6500.
44. Claret FX, Hibi M, Dhut S, Toda T, Karin M. A new group of conserved coactivators that increase the specificity of AP-1 transcription factors. Nature 1996;383(6599):453-457.
45. Rahmani M, Peron P, Weitzman J, Bakiri L, Lardeux B, Bernauau D. Functional cooperation between JunD and NF-kappaB in rat hepatocytes. Oncogene 2001;20(37):5132-5142.
46. Wang W, Jaiswal AK. Nuclear factor Nrf2 and antioxidant response element regulate NRH:quinone oxidoreductase 2 (NQO2) gene expression and antioxidant induction. Free Radic Biol Med 2006;40(7):1119-1130.
47. Basu HS, Thompson TA, Clower C, Church D, Mehraein F, Amlong CA, Madapathage T, Woster P, Wilding G. An Inhibition of Acetyl Polyamine Oxidase specifically blocks Androgen induced Oxidative Stress and Prevents occurrence of Prostate Cancer in Transgenic Adenocarcinoma of Mouse Prostate (TRAMP). Abstract presented at 18th Annual Conference of EORTC-AACR-NCI on Molecular Targets and Cancer Therapeutics. Prague, Czech Republic, November 7-10, 2006.
48. Cohen SS. A guide to the polyamines. Oxford, UK: Oxford University Press; 1998. pp. 296-319.
49. Bauer JA, Thompson TA, Church DR, Ariazi EA, Wilding G. Growth inhibition and differentiation in human prostate carcinoma cells induced by the vitamin D analog 1alpha,24-dihydroxyvitamin D2. Prostate 2003;55(3):159-167.
50. Ouyang X, DeWeese TL, Nelson WG, Abate-Shen C. Loss-of-function of Nkx3.1 promotes increased oxidative damage in prostate carcinogenesis. Cancer Res 2005;65(15):6773-6779.
51. Song YS, Lee BY, Hwang ES. Distinct ROS and biochemical profiles in cells undergoing DNA damage-induced senescence and apoptosis. Mech Ageing Dev 2005;126(5):580-590.